Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DNA X's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DNA X's regulatory disclosures and financial reporting.
Sonim Technologies filed a resale prospectus covering up to 19,444,444 shares of common stock that Chardan Capital Markets may sell from time to time. The shares may be issued to Chardan at Sonim’s discretion under a committed equity facility; Sonim is not selling securities in this prospectus and will not receive proceeds from Chardan’s resales. Sonim may receive up to $500.0 million in gross proceeds from Chardan when it sells shares to Chardan under the facility, with sales prices tied to market VWAP, subject to conditions and limits.
The facility runs for three years from effectiveness and is constrained by a 19.99% Nasdaq Exchange Cap without prior stockholder approval unless sales meet the Nasdaq Minimum Price of $11.2986, and a 4.99% Beneficial Ownership Limitation for Chardan. Shares outstanding were 1,015,652 as of September 30, 2025. Sonim also discloses Nasdaq deficiency letters and an extension through December 31, 2025 to address the minimum stockholders’ equity rule, and must meet the minimum bid price requirement by February 9, 2026 to maintain listing.
Sonim Technologies (SONM) filed its Q3 2025 10‑Q, reporting total net revenues of $16.214 million and a net loss of $4.753 million. For the nine months, revenues were $44.125 million with a net loss of $11.770 million. Gross profit declined year over year in the quarter as costs rose.
Liquidity is tight: cash and equivalents were $2.137 million at September 30, 2025, with $21.522 million used in operating cash flow year to date and a stockholders’ deficit of $0.701 million. The company disclosed substantial doubt about its ability to continue as a going concern.
Sonim entered an asset purchase agreement to sell substantially all assets of its enterprise 5G solutions business for $15,000 cash, plus up to $5,000 earn‑out, subject to closing conditions; once closed, there will be no more revenue from the existing business. To fund operations, Sonim completed a July public offering of 411,111 shares at $13.50 (net proceeds ≈ $4.8 million), sold 193,405 shares via ATM (net $8.229 million), and entered a ChEF committed equity facility. Debt outstanding includes promissory notes with $5.680 million principal. A 1‑for‑18 reverse split became effective on October 27, 2025; 1,028,693 shares were outstanding on October 28, 2025.
Sonim Technologies filed an 8-K stating it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
Sonim Technologies announced a reverse stock split of its common stock at a 1-for-18 ratio, approved by stockholders and the Board. The split will be effected by a certificate of amendment and will become effective at 12:01 a.m. Eastern Time on October 27, 2025.
Every eighteen shares will combine into one share with no change to par value. No fractional shares will be issued; holders entitled to a fraction will receive cash in lieu based on the October 20, 2025 closing price (as adjusted). The stock will begin trading on a split-adjusted basis on October 27, 2025 under the existing ticker SONM. The new CUSIP will be 83548F 408.
Sonim Technologies reported multiple corporate actions. Nasdaq granted an extension through December 31, 2025 to regain compliance with Listing Rule 5550(b)(1), which requires $2.5 million in stockholders’ equity. The company submitted a compliance plan and noted that failure to meet requirements could lead to delisting.
The board set a 1-for-18 reverse stock split expected to take effect at 12:01 a.m. ET on October 27, 2025, aimed at meeting the minimum bid price. Stockholders approved increasing authorized common shares from 100,000,000 to 1,000,000,000, which was filed and became effective on October 16, 2025. They also approved the reverse split authority, while a proposed 1,000,000‑share increase to the 2019 Equity Incentive Plan was not approved. A quorum was reached with 12,056,361 shares (about 67.8%) represented.
The board appointed Michael Mulica as Executive Chairman effective October 16, 2025, with a $300,000 base salary, an annual $250,000 RSU grant vesting quarterly over two years, and a $500,000 RSU award tied to a specified asset purchase, with cash substitutes possible if plan share availability is insufficient.
Sonim Technologies (SONM): Form 3 filed for a director
A director of Sonim Technologies filed an initial statement of beneficial ownership (Form 3). The filing reports direct ownership of 723 shares of common stock. The event date was 07/18/2025, and the form was filed by one reporting person. No derivative securities were reported.
Sonim Technologies, Inc. filed an amendment to its S-1 registration that registers shares for resale by Chardan and updates pro forma and distribution details. The company may issue up to 350,000,000 additional shares to Chardan under a purchase agreement, which combined with existing outstanding shares of 10,338,905 could total 360,338,905 shares offered for resale under certain assumptions. The Purchase Agreement limits issuance to no more than 19.99% of pre-transaction outstanding shares unless stockholder approval or the Nasdaq Minimum Price of $0.6277 is met; Chardan is further restricted from exceeding 4.99% beneficial ownership.
The company estimates it may receive up to $500.0M of aggregate gross proceeds from sales to Chardan, although actual proceeds depend on shares sold and prices; at least 33% of proceeds will prepay the July Note. Pro forma adjustments reflect an estimated transaction expense accrual of $1,250, severance of $2,137, recognition of a gain on an Asset Sale of $12,074, and application of a 21% statutory tax rate. The filing discloses potential FINRA conflict-of-interest compliance for Chardan acting as executing broker and includes customary risk factor and forward-looking statement language.
Sonim Technologies registers a shelf to allow resale by a selling securityholder and to support an at-the-market-style purchase agreement under which the company may sell up to 350,000,000 shares to Chardan. The company had 10,338,905 shares outstanding at June 30, 2025 in the disclosure and estimates it could receive up to $500.0 million in aggregate gross proceeds from sales to Chardan, subject to sales prices, discounts and Nasdaq issuance limits. At least 33% of proceeds from sales to Chardan would be applied to prepayment of the July Note. Issuances to Chardan are limited by a 19.99% Exchange Cap and a 4.99% beneficial ownership cap, and the Purchase Agreement contains a Nasdaq Minimum Price of $0.6277 per share. Resales by Chardan present a FINRA Rule 5121 conflict of interest; resales will follow FINRA procedures.
Sonim Technologies entered a committed equity facility with Chardan Capital Markets that allows Sonim, at its option, to sell newly issued common shares for up to $500,000,000 in aggregate gross purchase price, subject to limits including an exchange cap of 2,066,747 shares, equal to 19.99% of shares outstanding before the agreement. Sales will be priced off the stock’s volume weighted average price with a fixed 3.5% discount and can occur over a 36‑month period after the resale registration statement becomes effective.
Chardan’s beneficial ownership is capped at 4.99% of outstanding shares, and per‑day purchases are further limited by dollar, trading‑volume and contract thresholds. Sonim plans to use at least 33% of any proceeds to prepay a $2,755,000 promissory note to Streeterville Capital, with the balance intended for operations, working capital and general corporate purposes.
Sonim Technologies, Inc. is asking stockholders to vote at a Special Meeting on October 16, 2025 on four proposals: a reverse stock split, an increase in authorized common shares, an increase in shares under the equity incentive plan, and an adjournment proposal. The board proposes increasing authorized common stock from 100,000,000 to 1,000,000,000 shares and would raise shares reserved under the equity plan from 43,927 to 1,043,927 if approved. The company reports 17,781,919 shares outstanding and 80,381,720 shares available for issuance today (rising to 980,381,720 if the authorized increase is approved). The Nasdaq reported closing price is $0.7536 per share. Named executives include CEO Peter Hao Liu, CFO Clay Crolius, and CCO Charles Becher. Major holders disclosed include AJP/Orbic Group with 11.07%, Laurence Lytton 5.55%, CVI 5.62%, L1 5.62%, and 1 Main 5.07%. The board notes potential benefits of the reverse split but also identifies associated risks.